Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation
Research output: Contribution to journal › Journal article › Research › peer-review
Compelling evidence supports the existence of a profound immune dysregulation in patients with chronic myeloproliferative neoplasms (MPN). Increased Arginase-1 expression has been described in MPN patients and in solid cancers. This increase contributes to an immunosuppressive tumor microenvironment in MPN patients because of L-arginine depletion by Arginase-1-expressing regulatory cells and cancer cells, which subsequently limits the activation of circulating effector cells. In the present study, we demonstrate that Arginase-1-derived peptides are recognized by T cells among peripheral mononuclear blood cells from MPN patients. We characterized the Arginase-1-specific T cells as being CD4+ and found that the magnitude of response to the Arginase-1 peptides depends on disease stage. Activation of Arginase-1-specific T cells by vaccination could be an attractive novel immunotherapeutic approach to targeting malignant and suppressive cells in MPN patients in combination with other immunotherapeutics.
Original language | English |
---|---|
Article number | e1468957 |
Journal | OncoImmunology |
Volume | 7 |
Issue number | 9 |
Number of pages | 8 |
ISSN | 2162-4011 |
DOIs | |
Publication status | Published - 2018 |
- Arginase-1, immune responses, MPN, therapeutic peptide vaccine
Research areas
Links
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140593/pdf/koni-07-09-1468957.pdf
Final published version
ID: 208875526